Author:
Thieblemont Catherine,Coiffier Bertrand
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.Semin Oncol. 1999;26:66–73.
2. Grossbard ML, Fidias P, Kinsella J, et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.Brit J Haematol. 1998;102:509–515.
3. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131 - Anti-B1 radioimmunotherapy for B-cell lymphoma.J Clin Oncol. 1996;14: 1974–1981.
4. Witzig TE,White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 1999;17: 3793–3803.
5. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457–2466.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献